



Emerging Principles : a theory for robustness



12 October, ICSB2006
Yokohama



Manchester Centre for Integrative Systems Biology and BioCentrum Amsterdam

Opening lecture Hiroaki Kitano


- # We need a theory for systems biology,
notably for robustness
- # Robustness is a system property
- # Is robustness conserved?
- # Trade-off between robustness and
fragility (exact?)

For a theory of robustness



We need a definition of
robustness

An example of robustness



Definition of robustness *vis-à-vis* a perturbation




How robust is a function with respect to a perturbation in a property?

By what percentage can I perturb that property and still affect system function by only 1 %?

An example of robustness


$$\mathcal{R}_{e_i}^J \equiv \frac{5\% \text{ decrease in enzyme activity}}{1\% \text{ decrease in function (flux) } J} = 5$$



Robustness is a system property: Low robustness of processes in isolation

$$\mathcal{R}_{e_i}^J \equiv \frac{1\% \text{ decrease in enzyme activity}}{1\% \text{ decrease in function (flux) } J} = 1$$


Flux versus enzyme activity



An example of high robustness

$$\mathcal{R}_{e_i}^J \equiv \frac{23\% \text{ decrease in enzyme activity}}{1\% \text{ decrease in function (flux) } J} = 23$$



Flux versus enzyme activity



An example of lack of robustness (fragility)




$$\mathcal{R}_{e_i}^J \equiv \frac{0.1\% \text{ decrease in enzyme activity}}{1\% \text{ decrease in function (flux) } J} = 0.1$$

Flux versus enzyme activity



More precise definition of robustness



$$\mathfrak{R}_{e_i}^{function_j} \equiv \left(\frac{\partial \text{enzyme}_i / \text{enzyme}_i}{\partial function_j / function_j} \right)_{\text{all other parameters}} = \left(\frac{\partial \ln \text{enzyme}_i}{\partial \ln function_j} \right)_{\text{all other parameters}} = 1 / \left(\frac{\partial \ln function_j}{\partial \ln \text{enzyme}_i} \right)_{\text{all other parameters}}$$



Robustness



- # There is more than one definition
- # E.g. John Doyle's definition: frequency domain
- # This one: steady state function with respect to parameters, such as catalytic activities




Are robustnesses large?

Silicon cell live models: jjj.bio.vu.nl

JWSapplet: Glycolysis in *Trypanosoma brucei* - Bakker et al.

[Home](#) [Model Database](#) [Site information](#) [Contact info](#) [sbml](#)

	Parameter	Value
P28_v1	Vm7	1.
P29_v1	K7GAP	0.15
P30_v1	K7NAD	0.45
P31_v1	K7NADH	0.02
P32_v1	K7BPGA13	0.1
P33_v1	Vm8f	533
P34_v1	Vm8r	149.24
P35_v1	Vm8	1.
P36_v1	K8DHAPg	0.1
P37_v1	K8NADH	0.01
P38_v1	K8NAD	0.4
P39_v1	K8Gly3Pg	2
P40_v1	Vm9	18
P41_v1	K9Gly3Pc	1.7
P42_v1	Vm10	200
P43_v1	K10Pyr	1.96
P44_v1	Vm11f	640
P45_v1	Vm11r	18.56
P46_v1	Vm11	1.
P47_v1	K11BPGA13	0.05

POWERED BY  [Moi](#) [Reset](#)

Evaluate Model

Steady State


N matrix: $\dot{s} = N \cdot v$

K matrix: $J = K \cdot J_i$

L matrix: $s = L \cdot s_i + T$

Jacobian: $d(ds/dt)/ds$

Eigenvalues



Robustness of vital flux of Trypanosomes *vis-à-vis* perturbation of various glycolytic steps

step	Robustness
Glctr	1.1
GAPdh	42
HK	42
PGI	1546
PFK	234
ALD	38
TPI	482
GDH	66
GPO	-251
PGK	61
PK	691
ATPase	2744
GlyK	389

Yes, most robustnesses are large; average is 468 here

Systems Biology: principles



**Are there any principles vis-à-vis
this robustness?**



Is robustness conserved?

Is robustness conserved?

(e.g. when making the most fragile step robust)

step	Robustness	Robustness double glc transporter
Glctr	1.1	88
GAPdh	42	4
HK	42	20
PGI	1546	412
PFK	234	56.
ALD	38	3
TPI	482	64
GDH	66	6
GPO	-251	-15
PGK	61	7
PK	691	73
ATPase	2744	313
GlyK	389	26
Sum (average)	6085 (468)	1055(81)

No, robustness is not
conserved



No principles then?





Yes, there is one!

Sum over all inverse robustnesses = 1

step	1/robustness	1/robustness (doubled glc transporter)
Glctr	0.887	0.011
GAPdh	0.024	0.249
HK	0.024	0.051
PGI	0.001	0.002
PFK	0.004	0.018
ALD	0.026	0.354
TPI	0.002	0.016
GDH	0.015	0.166
GPO	-0.004	-0.068
PGK	0.016	0.144
PK	0.001	0.014
ATPase	0	0.003
GlyK	0.003	0.039
Sum	0.999	0.999

Systems Biology principle concerning robustness

$$\sum_{i=1}^n \frac{1}{\mathcal{R}_{e_i}^J} \equiv 1$$



Implications

- ⌘ Flux robustnesses can be homogeneous (robustness the same *vis-à-vis* all enzyme perturbations) or heterogeneous
- ⌘ Average robustness is higher when robustness is heterogeneous
- ⌘ By increasing fragility *vis-à-vis* one step one can increase the average robustness
- ⌘ Lowest robustness is best drug target

Opening lecture Hiroaki Kitano


- # We need a theory for systems biology,
notably for robustness 
- # Robustness is a system property 
- # Is robustness conserved? 
- # Trade-off between robustness and
fragility (exact?) 

Robustness of ERK phosphorylation



EGF initiated signal
transduction


ERK-PP in single cells upon EGF stimulation



Green: total ERK

Red: ERK-PP


ERK-PP profile upon EGF stimulation



Research questions

- ⌘ To which perturbations is this signal transduction robust (fragile)?
- ⌘ Does this differ for the various aspects of the signal?
- ⌘ Are there generic principles here?

Robustness of ERK-PP *vis-à-vis* perturbation



Robustness of ERK-PP amplitude in model MAP kinase pathway: mostly robust



	kinases			phosphatases				Sum
	1	2	3	1	2	3	R	
Amplitude	6	4	2	-7	-5	-3	-6	-9

Duration robustness in model MAP kinase pathway

	kinases			phosphatases				Sum
	1	2	3	1	2	3	R	
Amplitude	6	4	2	-7	-5	-3	-6	-9
Duration	17	11	8	-2	-3	-3	-8	20

Research questions

- ⌘ To which perturbations is this signal transduction robust (fragile)? **Most**
- ⌘ Does robustness differ for the various aspects of the signal?
- ⌘ Are there generic principles here?



Robustness depends on function considered and is not conserved

	kinases			phosphatases				Sum
	1	2	3	1	2	3	R	
Amplitude	6	4	2	-7	-5	-3	-6	-9
Duration	17	11	8	-2	-3	-3	-8	20

Systems Biology principle concerning robustness

$$\sum_{i=1}^n \frac{1}{\mathfrak{R}_{e_i}^{amplitude}} \equiv 0$$



Research questions

- ⌘ To which perturbations is this signal transduction robust (fragile)? **Most**
- ⌘ Does robustness differ for the various aspects of the signal? **Yes**
- ⌘ Are there generic principles here? **Yes**

Systems Biology principles concerning robustness differ

$$\sum_{i=1}^n \frac{1}{\mathfrak{R}_{e_i}^{amplitude}} \equiv 0$$

$$\sum_{i=1}^n \frac{1}{\mathfrak{R}_{e_i}^{duration}} \equiv -1$$





Incidentally, the math behind
these theorems....




Metabolic Control Analysis




Fragility *vis-à-vis* kinases and phosphatase perturbation?

- ⌘ Duration more than amplitude is fragile *vis-à-vis* phosphatase perturbation
- ⌘ Amplitude more than duration is fragile *vis-à-vis* kinase perturbation







Duration more than amplitude is fragile *vis-à-vis* phosphatases



Amplitude more than duration is fragile *vis-à-vis* kinases



Is it all true?

⌘ Duration fragility resides more in phosphatases




⌘ Amplitude more fragile vis-à-vis kinase activity



Detailed kinetic model of signaling by EGF


Schoeberl *et al.* (2002)



MAP kinase signaling: which steps are robust?

Mutations of the *BRAF* gene in human cancer

Helen Davies^{1,2}, Graham R. Bignell^{1,2}, Charles Cox^{1,2}, Philip Stephens^{1,2}, Sarah Edkins¹, Sheila Clegg¹, Jon Teague¹, Hayley Woffendin¹, Mathew J. Garnett³, William Bottomley¹, Neil Davis¹, Ed Dicks¹, Rebecca Ewing¹, Yvonne Floyd¹, Kristian Gray¹, Sarah Hall¹, Rachel Hawes¹, Jaime Hughes¹, Vivian Kosmidou¹, Andrew Menzies¹, Catherine Mould¹, Adrian Parker¹, Claire Stevens¹, Stephen Watt¹, Steven Hooper³, Rebecca Wilson³, Hiran Jayatilake⁴, Barry A. Gusterson⁵, Colin Cooper⁶, Janet Shipley⁶, Darren Hargrave⁷, Katherine Pritchard-Jones⁷, Norman Maitland⁸, Georgia Chenevix-Trench⁹, Gregory J. Riggins¹⁰, Darell D. Bigner¹⁰, Giuseppe Palmieri¹¹, Antonio Cossu¹², Adrienne Flanagan¹³, Andrew Nicholson¹⁴, Judy W. C. Ho¹⁵, Suet Y. Leung¹⁶, Siu T. Yuen¹⁶, Barbara L. Weber¹⁷, Hilliard F. Seigler¹⁸, Timothy L. Darrow¹⁸, Hugh Paterson³, Richard Marais³, Christopher J. Marshall³, Richard Wooster^{1,6}, Michael R. Stratton^{1,4} & P. Andrew Futreal¹





Oncogenes affect steps for which the system is least robust



**And increase the robustness
Tumor cell is more robust**


Emerging Principles of Living Systems: Robustness

- # Robustness, a quantitative definition
- # Example: robustness of the vital flux of Trypanosomes
 - ☒ Robustness is not conserved
 - ☒ General principle 1: fluxes
- # Robustness in signal transduction
 - ☒ General principle 2: amplitude
 - ☒ Duration fragile *vis-à-vis* phosphatases perturbation more than kinase perturbation
 - ☒ Amplitude also fragile *vis-a-vis* kinase perturbation
- # Oncogenes: may act to enhance robustness



Opening lecture Hiroaki Kitano

- # We need a theory for systems biology,
notably for robustness
 - # Robustness is a system property
 - # Is robustness conserved?
 - # Trade-off between robustness and
fragility (exact?)
- # Hiroaki was right!**



Thanks to:

and to you

Barbara Bakker

Frank Bruggeman


Reinhart Heinrich

Jorrit Hornberg

Jacky Snoep

and many others

Barbara Bakker
Frank Bruggeman
Reinhart Heinrich
Jorrit Hornberg



2nd FEBS Advanced Course Systems Biology



March 10-16, 2007
Gosau, Austria

www.febssysbio.net



Announcement FEBS-SysBio2007

2nd FEBS Advanced Lecture Course
**"Systems Biology:
From Molecules to Life"**
March 10 – 16, 2007
Sport & Erlebnis Hotel**** Gosau, Austria

Organizers

Hans Westerhoff (The Netherlands, UK)
Roland Eils (Germany)
Karl Kuchler (Austria)
Edda Klipp (Germany)
Uwe Sauer (Switzerland)

Supported by

FEBS AstraZeneca BMBF BioCentrum A'dam
Systems-X DKFZ DSM YSBN ESMTB
NucSys BioSim Helios Bioscience

Scientific Advisory Board (SAB)

Ruedi Aebersold	Lilia Alberghina
Uri Alon	Barbara Bakker
Marta Cascante	Igor Goryanin
Stefan Hohmann	Douglas Kell
Boris Kholodenko	Hiroaki Kitano
Ursula Klingmüller	Ursula Kummer
Erik Mosekilde	Steve Oliver
Bernhard Palsson	Masaru Tomita
Roel van Driel	Barry Wanner
Shoshana Wodak	

Deadline for online applications and abstract
submission: December 1, 2006
<http://www.FEBSSysBio.net>